Summary
Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H1 2016’, provides an overview of the Visceral Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Visceral Pain
- The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects
- The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Visceral Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Visceral Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Addex Therapeutics Ltd
Amorepacific Corporation
Aros Pharma ApS
Astellas Pharma Inc.
Echo Pharmaceuticals B.V.
GIcare Pharma Inc
Grunenthal GmbH
Nektar Therapeutics
Neurim Pharmaceuticals Ltd
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Visceral Pain Overview 8
Therapeutics Development 9
Pipeline Products for Visceral Pain - Overview 9
Pipeline Products for Visceral Pain - Comparative Analysis 10
Visceral Pain - Therapeutics under Development by Companies 11
Visceral Pain - Therapeutics under Investigation by Universities/Institutes 12
Visceral Pain - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Visceral Pain - Products under Development by Companies 15
Visceral Pain - Products under Investigation by Universities/Institutes 16
Visceral Pain - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Amorepacific Corporation 18
Aros Pharma ApS 19
Astellas Pharma Inc. 20
Echo Pharmaceuticals B.V. 21
GIcare Pharma Inc 22
Grunenthal GmbH 23
Nektar Therapeutics 24
Neurim Pharmaceuticals Ltd 25
Visceral Pain - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ADX-71441 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ADX-71743 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ASP-7663 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dronabinol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GIC-1002 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NEO-5024 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NEO-5937 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NeuP-12 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NKTR-195 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PAC-14028 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
piromelatine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PPC-5650 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PR-38 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RO-656570 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
URB-937 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Visceral Pain - Recent Pipeline Updates 56
Visceral Pain - Dormant Projects 60
Visceral Pain - Discontinued Products 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Visceral Pain, H1 2016 9
Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Visceral Pain - Pipeline by Addex Therapeutics Ltd, H1 2016 17
Visceral Pain - Pipeline by Amorepacific Corporation, H1 2016 18
Visceral Pain - Pipeline by Aros Pharma ApS, H1 2016 19
Visceral Pain - Pipeline by Astellas Pharma Inc., H1 2016 20
Visceral Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2016 21
Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2016 22
Visceral Pain - Pipeline by Grunenthal GmbH, H1 2016 23
Visceral Pain - Pipeline by Nektar Therapeutics, H1 2016 24
Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Visceral Pain Therapeutics - Recent Pipeline Updates, H1 2016 56
Visceral Pain - Dormant Projects, H1 2016 60
Visceral Pain - Dormant Projects (Contd..1), H1 2016 61
Visceral Pain - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Visceral Pain, H1 2016 9
Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Top 10 Targets, H1 2016 27
Number of Products by Stage and Top 10 Targets, H1 2016 27
Number of Products by Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Routes of Administration, H1 2016 31
Number of Products by Stage and Routes of Administration, H1 2016 31
Number of Products by Molecule Types, H1 2016 33
Number of Products by Stage and Molecule Types, H1 2016 33
